LTR Pharma (ASX:LTP) Retained Earnings: A$-20.83 Mil (As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.58
! 1 Warning Sign
View Full Analysis

What is LTR Pharma Retained Earnings?

LTR Pharma ASX:LTP 15 Retained Earnings is A$-20.83 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. LTR Pharma's retained earnings for the quarter that ended in Dec. 2025 was A$-20.83 Mil.

LTR Pharma's quarterly retained earnings declined from Dec. 2024 (A$-11.88 Mil) to Jun. 2025 (A$-15.07 Mil) and declined from Jun. 2025 (A$-15.07 Mil) to Dec. 2025 (A$-20.83 Mil).

LTR Pharma's annual retained earnings declined from Jun. 2023 (A$-3.86 Mil) to Jun. 2024 (A$-9.48 Mil) and declined from Jun. 2024 (A$-9.48 Mil) to Jun. 2025 (A$-15.07 Mil).

LTR Pharma  (ASX:LTP) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

LTR Pharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Retained Earnings Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
-0.04 -1.07 -3.86 -9.48 -15.07

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial -5.06 -9.48 -11.88 -15.07 -20.83
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of A$-20.83 Mil mean?
LTR Pharma (ASX:LTP) has a Retained Earnings of A$-20.83 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Retained Earnings too high?
LTR Pharma's current Retained Earnings is A$-20.83 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Retained Earnings compare to VRTX and REGN?
LTR Pharma's Retained Earnings of A$-20.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on LTR Pharma and its competitors. LTR Pharma's current Retained Earnings is A$-20.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Retained Earnings of A$-20.83 Mil. The current Retained Earnings is A$-20.83 Mil. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Retained Earnings is A$-20.83 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.58
Price